Please login to the form below

Not currently logged in
Email:
Password:

Alkopharma acquires rights to Navoban

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights.

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights. 

Alkopharma intends to commercialise the drug in more than 80 countries and will drive into new markets, such as the US, to reinforce the company's growing position globally.

Alain Bouaziz, Alkopharma's president and CEO, said the deal marked an exciting step for the company and maintained the ethical basis that the company was founded on 10 years ago.

Alkopharma acquires original molecules from large pharmaceutical companies that are no longer interested in manufacturing drugs from them, such as those used in orphan diseases. In this way, it attempts to meet patients' needs for personalised treatments for rare diseases.

A new manufacturing facility is to be built in Wallis, Switzerland, starting in January 2010, to support the company's R&D and expansion plans. It will house two units, one dedicated to the production of anti-tumour products and the other to biotech-derived products.

11th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics